Organic Process Research & Development 2009, 13, 292–296
Enzymatic Resolution of N-Substituted-ꢀ-prolines
,†
,†
†
†
‡
‡
´
Javier Mendiola,* Susana Garc´ıa-Cerrada,* Oscar de Frutos, Mar´ıa Luz de la Puente, Rui Lin Gu, and Vien V. Khau
Centro de InVestigacio´n Lilly S.A. AVda. de la Industria, 30 Alcobendas-Madrid 28108, Spain, and Eli Lilly & Company,
LTC-South, Indianapolis, Indiana 46285-4813, U.S.A.
Abstract:
upon the development of an automated enzymatic screen and
an efficient analytical methodology (that measures yield and
the enantiomeric excess in a single experiment) capable to
efficiently provide us those valuable key intermediates.
A general and straightforward strategy for enzymatic resolution
of N-substituted-ꢀ-proline has been successfully designed and
developed in our research laboratories. A first affinity screen is
followed by ratio enzyme/substrate optimization to source our
chemistry groups N-substituted-ꢀ-proline in kilogram scale in an
efficient and cost-effective way.
2. Results and Discussion
The synthesis of ꢀ-prolines (3a-c) was achieved by adjust-
ing the procedure described in the literature (Scheme 1).3-5 1,3-
Cycloaddition of N-methoxy-N-trimethylsilylbenzylamine (1)
to methyl acrylate in acidic medium yielded pyrrolidine (2) in
high yield.3 Formation of corresponding hydrochloride salt 3a
allowed the easy isolation of highly pure material without any
chromatographic step. Conventional debenzylation by hydro-
genation yielded the desired pyrrolidine (4) in 98% yield (all
attempts with the free amine always provided decomposition
products).4 ꢀ-Proline hydrochloride (4) was used as a key
intermediate to prepare the two different pyrrolidines derivatives
(N-boc 3b5 and N-Cbz 3c6) envisioned to be included in our
enzymatic screen because of their electronic behavior and
synthetic availability.
A set of 13 commercial available hydrolytic enzymes was
selected for a preliminary screen.7 All tests were run in aqueous
medium (phosphate buffer pH 7.5; C, 0.1 M, rt; Scheme 2).The
conversion and optical purity were determined by achiral
reversed-phase HPLC/MS and chiral GC, respectively.
The results for each substrate after 24 h of incubation are
summarized in Table 1. For 3c (Cbz), lipases PS, AY30, PPL,
CCL, proteases P, PS, and acylase overreacted (conversion C
∼100%); lipases AK, AS, FAP15, and M (Table 1, entries 1-4)
showed conversions close to 50% but only lipase M (Mucor
jaVanicus) gave promising results: C, 60%; ee, 92%; and E,8
13 (Table 1, entry 2). When working with substrate 3a,
conversion could not be determined because of the difficulties
found for the isolation of the corresponding carboxylic acid
(zwitterionic behavior). Nevertheless, chiral GC allowed for the
determination of the chiral purity of the remaining ester.
Unfortunately, in all cases, ee was found to be <50% (Table
1, entries 5-17).
1. Introduction
Investigative pharmaceutical agents typically contain multiple
functional groups and one or more stereocenters, and must be
isolated in high chiral as well as chemical purity. Classical
resolution or chiral chromatography can be useful in the
preparation of these drug candidates in enantiomerically pure
form. However, those approaches also show certain drawbacks.
Hence, for instance, resolutions often suffer from low overall
yield and normally require the presence of accessible acidic or
basic functionalities. However, chiral chromatography can be
sometimes solvent and time intensive. A selective synthesis that
yields the desired functionalities in high chemo, enantio, and/
or diastereo control is, therefore, greatly desirable. In this
context, biocatalysis plays an increasing role due to the benefits
associated with those types of processes, such as speed,
selectivity, or ability to quantity.1 Screen of commercially
available enzymes can easily allow the rapid identification of
hits. Further process development involving a more detailed
study to optimize reaction parameters such as temperature,
solvent composition, or rate of addition can then supply the
desired synthetic intermediates in both high yield and high
optical purity.
N-Substituted-ꢀ-prolines are of great interest because of their
biological properties.2 Hence, any valuable technology for the
selective preparation of those type of substrates deserves special
attention. For all these reasons, we decided to focus our efforts
* To whom correspondence should be addressed. E-mail: mendiola_javier@
lilly.com, susana.garcia@lilly.com.
† Centro de Investigacio´n Lilly S.A. Avda. de la Industria.
‡ Eli Lilly & Company.
(1) (a) Patel, R. N. Stereoselective Biocatalysis for Synthesis of Some
Chiral Pharmaceutical Intermediates. In StereoselectiVe Biocatalysis;
CRC Press: Boca Raton, FL, 2000; Vol. 8, pp 7-130. (b) Patel, R. N.
Curr. Org. Chem. 2006, 10, 1289–1321.
(3) Yan, L.; Hale, J. J.; Lynch, C. L.; Budhu, R.; Gentry, A.; Mills, S. G.;
Hajdu, R.; Keohane, C. A.; Rosenbach, M. J.; Milligan, J. A.; Shei,
G.-J. Bioorg. Med. Chem. Lett. 2004, 14, 4861–4866.
(4) Delaney, E. J.; Wood, L. E.; Klotz, I. J. Am. Chem. Soc. 1982, 104,
799–807.
(2) (a) Karoyan, P.; Sagan, S.; Lequin, O.; Quancard, J.; Lavielle, S.;
Chassaing, G. Targets Heterocycl. Syst. 2004, 8, 216–273. (b) Cardillo,
G.; Gentilucci, L.; Tolomelli, A.; Calienni, M.; Qasem, A. R.;
Spampinato, S. Org. Biomol. Chem. 2003, 1, 1498–1502. (c) Hattori,
K.; Yamada, A.; Kuroda, S.; Chiba, T.; Murata, M.; Sakane, K. Bioorg.
Med. Chem. Lett. 2002, 12, 383–386. (d) Wood, S. J.; Wetzel, R.;
Martin, J. D.; Hurle, M. R. Biochemistry 1995, 34, 724–730. (e)
Johnson, G.; Drummond, J. T.; Boxer, P. A.; Bruns, R. F. J. Med.
Chem. 1992, 35, 233–241. (f) Nielsen, L.; Brehm, L.; Krogsgaard-
Larsen, P. J. Med. Chem. 1990, 33, 71–77.
(5) MacLeod, A. M.; Baker, R.; Freedman, S. B.; Patel, S.; Merchant,
K. J. J. Med. Chem. 1990, 33, 2052–2059.
(6) Murphy, J. A.; Tripoli, R.; Khan, T. A.; Mali, U. W. Org. Lett. 2005,
7, 3287–3289.
(7) Lipases AK, AS; FAP15, AY30, R, M, and PGE (Amano Co., Japan);
proteases N, P, and PS (Amano Co., Japan); acylase (Amano Co.,
Japan); lipases PPL, and CCL (Sigma, U.S.A.).
(8) Chen, C. S.; Fujimoto, Y.; Girdaukas, G.; Sih, C. J. J. Am. Chem.
Soc. 1982, 104, 7294.
292
•
Vol. 13, No. 2, 2009 / Organic Process Research & Development
10.1021/op8002097 CCC: $40.75
2009 American Chemical Society
Published on Web 11/12/2008